(1-(3,4-dichlorobenzyl)piperidin-3-yl)methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-(3,4-dichlorobenzyl)piperidin-3-yl)methanol
• 英文别名: 1-(3,4-Dichlorobenzyl)-3-hydroxymethylpiperidine；[1-(3,4-Dichloro-benzyl)-piperidin-3-yl]-methanol；[1-[(3,4-dichlorophenyl)methyl]piperidin-3-yl]methanol
• 化学式: C₁₃H₁₇Cl₂NO
• mdl: MFCD00814295
• 分子量: 274.19
• InChiKey: DSMFHKZBPHLJGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-哌啶甲醇 、 3,4-二氯苯甲醛 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 21.0h， 以86%的产率得到(1-(3,4-dichlorobenzyl)piperidin-3-yl)methanol
  参考文献：
  名称：

  Novel non-ATP competitive small molecules targeting the CK2 α/β interface

  摘要：

  Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2 alpha and CK2 beta at the alpha-beta interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 mu M and a molecular weight of only 257 gmol(-1) has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2 alpha. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.

  DOI：

  10.1016/j.bmc.2018.05.011

文献信息

• NOVEL PYRIMIDINE DERIVATIVE
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0760368A1

  公开（公告）日：1997-03-05

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula (I) wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1-C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1-C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1-C6 alkyl group, a C3-C6 cycloalkyl group, an aryl group or the like; R4 is -SR7 or -NR8R9 wherein R7 is a C1-C6 alkyl group; R8 is a C1-C6 alkyl group or the like; R9 is a hydrogen atom, a C1-C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) wherein R10 represents a C1-C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  可用作胃肠促动力药的嘧啶衍生物，由式（I）表示 其中 X 是 O 或 NR5，Y 是 O、S 或 NR5，其中 R5 是氢原子、C1-C6 烷基或类似物； R1 和 R2 可以相同或不同，各自为氢原子、C1-C6 烷基或类似物； R3 是 CN 或 COOR6，其中 R6 是 C1-C6 烷基、C3-C6 环烷基、芳基或类似基团； R4 是-SR7 或-NR8R9，其中 R7 是 C1-C6 烷基； R8 是 C1-C6 烷基或类似基团； R9是氢原子、C1-C6烷基或类似基团，或R8和R9可与它们所连接的氮原子一起代表式(X)的N-取代的哌嗪环 其中 R10 代表 C1-C6 烷基或类似基团或其药理学上可接受的盐。 上述化合物可用作治疗消化道疾病的胃肠促动力药。
• PYRIMIDINE DERIVATIVES
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0760368B1

  公开（公告）日：1999-07-28
• US5736550A
  申请人：——

  公开号：US5736550A

  公开（公告）日：1998-04-07
• Novel non-ATP competitive small molecules targeting the CK2 α/β interface
  作者：Paul Brear、Andrew North、Jessica Iegre、Kathy Hadje Georgiou、Alexandra Lubin、Laura Carro、William Green、Hannah F. Sore、Marko Hyvönen、David R. Spring

  DOI：10.1016/j.bmc.2018.05.011

  日期：2018.7

  Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2 alpha and CK2 beta at the alpha-beta interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 mu M and a molecular weight of only 257 gmol(-1) has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2 alpha. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.